[go: up one dir, main page]

WO2011148352A1 - Bactéries d'acide lactique destinées à la maturation du système nerveux entérique chez les nouveau-nés - Google Patents

Bactéries d'acide lactique destinées à la maturation du système nerveux entérique chez les nouveau-nés Download PDF

Info

Publication number
WO2011148352A1
WO2011148352A1 PCT/IB2011/052336 IB2011052336W WO2011148352A1 WO 2011148352 A1 WO2011148352 A1 WO 2011148352A1 IB 2011052336 W IB2011052336 W IB 2011052336W WO 2011148352 A1 WO2011148352 A1 WO 2011148352A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
infants
lactic acid
acid bacteria
cncm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2011/052336
Other languages
English (en)
Inventor
Biliana Lesic
Michel Neunlist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Gervais Danone SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Gervais Danone SA
Publication of WO2011148352A1 publication Critical patent/WO2011148352A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium

Definitions

  • the present invention relates to the field of infant nutrition, in particular to infant nutrition comprising lactic acid bacteria for use in maturation of the enteric nervous system in newly born infants.
  • the enteric nervous system consists of a complex network of neurons organized in several plexuses, which interacts by means of neurotransmitters such as acetylcholine and nitric oxide.
  • the ENS modulates the gastro-intestinal motility, and secretions of exocrine and endocrine origin independent of the central nervous system.
  • the ENS is for the most part developed before birth, the maturation of neurons and nerve plexuses continues after birth for a limited period of time. Especially in preterm infants the ENS is immature at birth, and there is a longer period after birth in which the ENS must further mature.
  • a mature ENS is required to ensure a normal pattern of intestinal motility in order to regulate digestion after birth.
  • Gastro-intestinal motility is required for normal transit of the contents of the gastro-intestinal lumen and the mixing of nutrients with digestive secretions. Abnormal development of any of the participants in gastro-intestinal motility results in significant morbidity and mortality, in particular in preterm infants.
  • WO 2004/1 12509 discloses a composition for inducing a pattern of gut barrier maturation similar to that observed with breast feeding and able to improve gut barrier maturation, e.g. during neonatal stress.
  • EP 1 161 152 discloses a nutritional composition intended for specific gastro-intestinal maturation in premature mammals.
  • ENS enteric nervous system
  • a composition with lactic acid bacteria or a strain of lactic acid bacteria is therefore advantageously used in infants for decreasing gastro-intestinal transit time, increasing gastro-intestinal motility, increasing gastro-intestinal muscle contractility, increasing gastro-intestinal peristalsis, preventing delayed gastric emptying, increasing coordinated contractions of the gastro-intestinal system, decreasing the time of meconium evacuation after birth, decreasing the time at which gastro-intestinal motility starts after birth, permitting earlier enteral feeding (tolerance) after birth, and/or reducing parental feeding time after birth.
  • a composition with lactic acid bacteria or a strain of lactic acid bacteria is therefore advantageously used in infants for treating and/or preventing an ENS related disorder selected from the group consisting of ileus, gastroparesis, abdominal distention, laparoschisis, dysmotility syndrome (such as constipation), and intestinal obstruction (such as atresia).
  • an ENS related disorder selected from the group consisting of ileus, gastroparesis, abdominal distention, laparoschisis, dysmotility syndrome (such as constipation), and intestinal obstruction (such as atresia).
  • the present composition with lactic acid bacteria is advantageously used in preterm infants. Also Caesarean section delivered infants, having a delayed intestinal colonization, will especially benefit from the present invention.
  • the present composition is preferably administered rectally.
  • the invention provides lactic acid bacteria strains and compositions comprising at least one strain of lactic acid bacteria, preferably strains selected from the group consisting of Lactobacillus and Bifidobacterium, more preferably Bifidobacterium, for use in infants for obtaining improvements of the enteric nervous system, in view of improving its maturation and/or of treating and/or preventing enteric nervous system related disorders.
  • Lactic acid producing bacteria used in the present invention are preferably provided as a mono- or mixed culture.
  • Lactic acid bacteria as referred to in the present invention consists of the genera Bifidobacterium, Lactobacillus, Carnobacterium, Enter ococcus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella.
  • the lactic acid bacteria used in the present invention comprises bacteria of the genus Lactobacillus and/or Bifidobacterium.
  • Bifidobacterium is the dominant genus in the intestinal microbiota of breast-fed infants and is preferred over Lactobacillus.
  • Bifidobacteria are Gram-positive, anaerobic, rod-shaped bacteria.
  • the Bifidobacterium species used in the present invention preferably have at least 95 % identity of the 16S rRNA sequence when compared to the type strain of the respective Bifidobacterium species, more preferably at least 97% identity as defined in handbooks on this subject, for instance Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989), Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor (N.Y.) Laboratory Press.
  • the Bifidobacteria preferably used are also described by Scardovi V., Genus Bifidobacterium, p.1418 - p.1434, Bergey's manual of systematic Bacteriology, Vol. 2, Sneath, P.H.A., N.S. Mair, M.E. Sharpe and J.G. Holt (ed.), Baltimore: Williams & Wilkins, 1986, 635 p.
  • the lactic acid producing bacteria used for fermentation comprises or is at least one Bifidobacterium selected from the group consisting of B. breve, B. infantis, B. bifidum, B. catenulatum, B. adolescentis, B. thermophilu , B.
  • B. animalis or lactis B. angulatum, B. pseudo catenulatum, B. thermacidophilum and B. Longum, more preferably B. breve, B. infantis, B. bifidum, B. catenulatum, B. longum, even more preferably B. animalis and B. breve, most preferably B. breve DN 156 007 (CNCM 1-2219 deposited on May 31 th 1999) disclosed in International patent application WO 01/01785, B. breve DN-156 032 (CNCM 1-4321, deposited on May 19, 2010), B. animalis ATCC SD5220, B. animalis DN 173 010 (CNCM 1-2494 deposited on June 20 th , 2000) disclosed in International patent application WO 02/02800.
  • Lactobacilli are Gram-positive, anaerobic, rod-shaped bacteria.
  • the present Lactobacillus species preferably have at least 95 % identity of the 16S rRNA sequence when compared to the type strain of the respective Lactobacillus species, more preferably at least 97% identity as defined in handbooks on this subject for instance Sambrook J., Fritsch, E.F., and Maniatis, T. (1989), Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor (N.Y.) Laboratory Press.
  • the lactic acid producing bacteria used for fermentation comprises at least one, more preferably at least two Lactobacillus species selected from the group consisting of L. casei, L. re teri, L. paracasei, L.
  • L. acidophilus L. johnsonii, L. lactis, L. salivarius, L. crispatus, L. gasseri, L. helveticus, L. zeae, L. fermentum and L. plantarum, more preferably L. casei, L. paracasei, L. rhamnosus, L. johnsonii, L. acidophilus, L. plantarum, L. fermentum and even more preferably L. plantarum strain DN 121 0304 (CNCM 1-4318 deposited on May 19 th 2010).
  • the present invention also provides new strains of lactic acid producing bacteria which are particularly suitable for uses according to the invention, and in particular in the compositions of the invention. These are strains DN 156 032 (CNCM 1-4321) and DN 121 0304 (CNCM 1-4318), which have been deposited according to the Budapest Treaty, on May 19, 2010 at Collection Nationale de Cultures de Microorganismes, 25 rue du Dondel Roux, Paris.
  • B. breve strain DN 156 032 (CNCM 1-4321) has the following fermentation profile when tested on an API 20A gallery: Fermentation of D-glucose, D- mannitol, D-lactose, D-saccharose, D-maltose, salicin, D-xylose, L-arabinose, D-cellobiose, D-mannose, D-melezitose, D-raffinose, sorbitol. It also has the following characteristics: no spores formed, Gram + staining, and no coccoid forms.
  • L. plantarum strain DN 121 0304 has the following fermentation profile when tested on an API 50 CH gallery: L-arabinose, D-xylose, D- galactose, D-glucose, D-fructose, D-mannose, D-mannitol, N-acetyl-glucosamine, amygdalin, arbutin, esculin, salicin, D-cellobiose, D-maltose, D-lactose, D-melibiose, D- saccharose, D-trehalose, D-melezitose, D-raffinose, gentiobiose, potassium gluconate.
  • the present composition comprises lactic acid producing bacteria in an amount of at least l lO 2 cfu per g dry weight of the final composition, more preferably at least lxl 0 4 cfu, even more preferably at least lxl 0 5 cfu.
  • the present composition comprises lactic acid bacteria in an amount less than lxl 0 1 1 cfu per g based on dry weight of the final composition, more preferably less than lxlO 10 cfu, even more preferably less than lxl 0 9 cfu per g dry weight.
  • the present composition when present as a liquid, comprises lactic acid producing bacteria in an amount of at least l xl O 3 cfu per 100 ml of the final composition, more preferably at least lxl O 5 cfu, even more preferably at least lxl 0 6 cfu.
  • the present composition when present in liquid form, comprises lactic acid producing bacteria in an amount of less than lxlO 12 cfu per 100 ml of the final composition,
  • the present composition when present as a supplement, such as human milk fortifier, depository, pill, tablet or enema, comprises lactic acid bacteria in an amount of at least lxl 0 3 cfu per g dry weight, more preferably at least lxl 0 5 cfu, even more preferably at least lxl 0 6 cfu.
  • the present composition when present as a supplement, such as human milk fortifier, depository, pill, tablet or enema, comprises lactic acid bacteria in an amount of less than 1x10 cfu per g based on dry weight of the final
  • 1 1 8 composition more preferably less than 1x10 cfu, even more preferably less than 1x10 cfu per g dry weight.
  • the cells are preferably inactivated.
  • Living bacterial cells are preferably inactivated by methods selected from the group consisting of heat treatment, UV treatment, sonication, treatment with oxygen, treatment with bactericidals such as ethanol, ultra high pressure application, high pressure homogenisation and/or use of a cell disruptor.
  • the lactic acid producing bacteria are heat killed after fermentation of the milk-derived product.
  • Preferable ways of heat killing are pasteurization, sterilization, ultra high temperature treatment, spray cooking and/or spray drying at temperatures bacteria do not survive.
  • Cell fragments are preferably obtained by heat treatment, sonication, treatment with bactericides such as ethanol, ultra high pressure application, high pressure homogenisation and/or use of a cell disruptor.
  • the fermented product Preferably intact cells of bacteria are removed from the fermented product by physical elimination such as filtration or centrifugation, for example centrifugation at 1 h at 3000 g, with the intact cells remaining in the pellet or retentate and the cell fragments remaining in the supernatant and/or filtrate, respectively.
  • the inactivation and/or physical removal of living cells is such that the amount of living lactic acid producing bacteria is below detection limit as used by conventional plating techniques known in the art. This detection limit is less than 10 cfu living cells of lactic acid producing bacteria based on g dry weight composition.
  • Inactivation of living cells has the advantage that, after production, the final nutritional composition can be pasteurised and/or sterilised, consequently reducing the chance of contamination with harmful micro-organisms, such as E. sakazakii. This is especially of importance for preterm infants and/or caesarean delivered infants since they are more prone to infections.
  • the present invention enables liquid, ready-to-use formula to be prepared and stored at room temperature. Furthermore, the dose of bioactive components received by each infant can be more easily controlled, since no further growth in a liquid product occurs, nor growth in the intestinal tract of the infant. The latter is a variable factor depending on the individual's intestinal environment, and thereby leads to variations in the extent of beneficial effects in individual infants.
  • the nutritional composition can be stored more easily and with reduced costs, since no special precautions have to be taken to maintain the viability of lactic acid producing bacteria at an acceptable level. This is especially the case in products with a water activity above 0.3. Also no post-acidification occurs in stored products with a high water activity and/or in infant formula in the period after reconstitution with water and before consumption. Adverse effect relating to coagulation of proteins and adverse taste are avoided in this way.
  • the present nutritional composition comprises inactivated lactic acid producing bacteria and/or bacterial fragments derived from lactic acid producing bacteria obtained from more than lxlO 2 cfu lactic acid producing bacteria per g based on dry weight of the final composition, more preferably lxl 0 4 cfu, even more preferably lxl 0 5 cfu.
  • the inactivated bacteria or bacterial fragments are obtained from less than lxl 0 1 ! cfu lactic acid producing bacteria per g based on dry weight of the final composition, more preferably lxl0 10 cfu, even more preferably lxl0 9 cfu.
  • composition is a fermented product.
  • composition used in the present invention are preferably nutritional and/or pharmaceutical compositions and suitable for administration to infants.
  • the present composition is preferably enterally administered.
  • Enteral administration includes oral administration, administration via a tube, which can end in the stomach or the duodenum, and rectal administration.
  • the composition is preferably a nutritional formula, preferably an infant formula.
  • the present composition can be advantageously applied as a complete nutrition for infants.
  • the present composition preferably comprises a lipid component, protein component and carbohydrate component and is preferably administered in liquid form.
  • the present invention includes dry food (e.g. powders) which is accompanied with instructions as to mix said dry food mixture with a suitable liquid (e.g. water).
  • Oral administration or administration via a tube has the advantage that the lactic acid bacteria also may have the beneficial effect in the small intestine, when they pass the gastro-intestinal tract.
  • the present invention advantageously provides an enteral food composition wherein preferably the lipid provides 5 to 50% of the total calories, the protein provides 5 to 50% of the total calories, and the digestible carbohydrates provides 15 to 90% of the total calories.
  • the lipid provides 35 to 50%) of the total calories
  • the protein provides 7.5 to 12.5% of the total calories
  • the digestible carbohydrate provides 40 to 55% of the total calories.
  • Protein is measured as the amount of nitrogen determined by Kjeldahl x 6.38 for milk protein and x 6.25 for non-milk protein.
  • the present composition preferably comprises at least one lipid selected from the group consisting of animal lipid (excluding human lipids) and vegetable lipids.
  • the present composition comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, animal oil, algae oil, fungal oil, and bacterial oil.
  • the present composition excludes human milk.
  • the protein used in the nutritional preparation is preferably selected from the group consisting of non-human animal proteins (preferably milk proteins), vegetable proteins (preferably soy protein and/or rice protein), hydrolysates thereof, free amino acids and mixtures thereof.
  • the present composition preferably contains casein, whey, hydrolysed casein and/or hydrolysed whey protein. The use of hydrolysed proteins advantageously improves the absorption of the dietary protein component by the immature intestine of the infant.
  • the present composition preferably comprises digestible carbohydrates selected from the group consisting of sucrose, lactose, glucose, fructose, corn syrup solids, starch and maltodextrins, more preferably lactose.
  • the present composition preferably has a viscosity between 1 and 60 mPa.s, preferably between 1 and 20 mPa.s, more preferably between 1 and 10 mPa.s, most preferably between 1 and 6 mPa.s.
  • the low viscosity ensures a proper administration of the liquid, e.g. a proper passage through the whole of a nipple or a tube. Also this viscosity closely resembles the viscosity of human milk. Furthermore, a low viscosity results in a normal gastric emptying and a better energy intake, which is essential for infants who need the energy for optimal growth and development.
  • the present composition is preferably prepared by admixing a powdered composition with water.
  • the present invention thus also relates to a packaged powder composition wherein said package is provided with instruction to admix the powder with a suitable amount of liquid, thereby resulting in a liquid composition with a viscosity between 1 and 60 mPa.s.
  • the viscosity of the liquid is determined using a Physica Rheometer MCR 300 (Physica Messtechnik GmbH, Ostfilden, Germany) at a shear rate of 95 s "1 at 20 °C.
  • Stool irregularities e.g. hard stools, insufficient stool volume, and diarrhoea
  • Stool irregularities are an important problem in infants. It was found that stool problems may be reduced by administering the non-digestible oligosaccharides present in liquid food with an osmolality between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg.
  • the liquid food does not have an excessive caloric density, however still provides sufficient calories to feed the subject.
  • the liquid food preferably has a caloric density between 0.1 and 2.5 kcal/ml, even more preferably a caloric density of between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.8 kcal/ml.
  • the infant formula is especially adapted to be suitable for feeding preterm infants or small for gestational age (SGA) infants.
  • the enteral composition of the present invention preferably comprises lipid providing 35 to 50% of the total calories, protein providing 10 to 20% of the total calories, and digestible carbohydrate providing 30 to 50 % of the total calories.
  • the lipid preferably comprises at least 15 % medium chain fatty acyl chains, having a length of from 6 to 12 carbon atoms, based on total fatty acids. Such medium chain fatty acyl chains are better digested by preterm or SGA infants.
  • the present composition is administered as a human milk fortifier (HMF).
  • HMF human milk fortifier
  • HMF are compositions that are added to human milk, e.g. obtained either from the infants own mother or from a donor, in order to supplement the milk with extra nutrients.
  • Human milk fortifiers are usually present as dose units which can be added to the human milk, mixed and subsequently the fortified human milk is administered to the infant.
  • Feeding an infant with a HMF comprising lactic acid bacteria is especially advantageous for preterm or small for gestational age (SGA) infants. This administration is enterally and may be orally via a bottle with a teat or by tube feeding.
  • the dose units are sachets comprising 0.5-10 g based on dry weight, more preferably 1-8 g, even more preferably 2-4 g.
  • the human milk fortifier is a reconstitutable powder.
  • a reconstitutable powder is a powder which can be dissolved in an aqueous liquid. Powdered human milk formulae have the advantage that they minimize the volume displacement of human milk.
  • the HMF is administered in a quantity of 0.1 to 20 g dry weight per day, more preferably 0.5 to 10 g dry weight per day.
  • the invention concerns a container comprising a human milk fortifier according to the invention in the form of a powder in an amount of from about 0.5 g to about 10 g per unit dose.
  • the human milk fortifier is present in the form of a concentrated liquid.
  • Use of concentrated liquid human milk fortifiers may reduce the risk of microbial contamination associated with the preparation of an infant feeding. This is especially important in case of preterm infants.
  • the HMF comprises besides the protein and fat component also digestible carbohydrates.
  • the HMF preferably comprises at least 10 % digestible carbohydrates based on total calories, more preferably at least 20 %, even more preferably at least 30 % based on total calories.
  • the HMF does not comprise more than 70 % digestible carbohydrates based on total calories, even more preferably not more than 50 % based on total calories.
  • the present HMF comprises at least 10 wt.% digestible carbohydrate based on dry weight, more preferably at least 20 wt.%, even more preferably at least 35 wt.% based on dry weight of the HMF.
  • the HMF does not comprise more than 75 wt.% digestible carbohydrate based on dry weight, more preferably not more than 60 wt.%, even more preferably not more than 50 wt.% based on dry weight.
  • Suitable sources of digestible carbohydrates are lactose and maltodextrin. Lactose advantageously resembles the carbohydrates source in human milk. Maltodextrin advantageously decreases the overall osmolality of the HMF.
  • a low osmolality of the present HMF will advantageously not increase the osmolality of the human milk after fortification.
  • a too high osmolality of the fortified human milk increases the risk on necrotizing enterocolitis (NEC). NEC is especially a problem in preterm and/or SGA infants. Therefore the present fortified human milk when fortified with the present HMF preferably has an osmolality between 300 and 480 mOsm/kg.
  • the present invention is administered rectally or anally, for instance in the form of a suppository or enema.
  • infants relate to human subjects with an age of 0 to 36 months, preferably 0 to 12 months.
  • the present composition is administered to human subjects with the age of 0-36 months, more preferably an age of 0 to 12 months, even more preferably 0 to 6 months, most preferably from 0 to 2 months. The younger the infant is, the more effect on ENS maturation will be.
  • the present invention preferably relates to a method for feeding premature infants and/or small for gestational age (SGA) babies.
  • a premature infant relates to an infant born before the standard period of pregnancy is completed, i.e. before or on 37 weeks from the beginning of the last menstrual period of the mother.
  • SGA babies are those whose birth weight lies below the 10th percentile for that gestational age. They have usually been the subject of intrauterine growth restriction (IUGR).
  • Premature and/or SGA infants include low birth weight infants (LBW infants), very low birth weight infants (VLBW infants), and extremely low birth weight infants (ELBW infants).
  • LBW infants are defined as infants with a weight less than 2500 g.
  • VLBW infants as infants with a weight which is less than 1500 g
  • ELBW infants as infants with a weight less than 1000 g.
  • Preterm infants are very vulnerable, especially in the first week after birth, and have an immature ENS.
  • the present invention preferably relates to the enteral administration of the composition of the present invention to infants delivered via caesarean section.
  • a caesarean section (c-section) is a surgical procedure where an infant is delivered through an incision made in the mother's abdominal wall, and then through the wall of the uterus.
  • a caesarean section is usually performed when it is safer for the mother or the infant than a vaginal delivery. Other times, a woman may choose to have a caesarean section rather than deliver her infant vaginally.
  • C-section infants have a delayed and impaired colonization of the intestine after birth. Therefore the further maturation of the ENS is impaired in such infants.
  • Most preferably the present composition is for use in preterm and/or SGA infants who are delivered by C-section.
  • the present composition is preferably enterally administered, more preferably orally.
  • the present composition is therefore preferably a liquid.
  • enteral here used also encompasses a rectal or anal administration.
  • the present composition is administered rectally or anally to the infant in a small volume, e.g. by "inoculating" the infant.
  • the present composition is administered to the infant as an enema with a syringe, pipette or tube, or in the form of a pill, tablet or suppository.
  • the present invention also provides a suppository, pill or table suitable for rectal administration to an infant, wherein said suppository, pill or tablet contains lactic acid bacteria.
  • the present invention also provides a method for administering to the infant within the first month after birth, preferably within two weeks after birth, more preferably within one week after birth, most preferably within 48 hours after birth.
  • the present invention provides a container comprising a liquid composition with a volume between 0.5 and 50 ml, which contains the present composition.
  • the liquid with the present lactic acid bacteria can be suitably used in the present method.
  • the liquid has a volume between 0.5 and 25 ml. This volume is preferably small, because it otherwise could interfere with the appetite and drinking behaviors of the infant.
  • a container with a reconstitutable dry composition containing the present composition wherein the container has a volume of between 0.5 and 50 ml.
  • This container is preferably accompanied with instruction to reconstitute the powder in a small volume of liquid, e.g. water.
  • the present composition is preferably administered at least once a day to the infant in need thereof.
  • the frequency of administration and the dosage of said composition depend, for example, upon the delivery vehicle and the infant to whom the composition is administered. It is within the level of knowledge of one of skill in the art to determine the frequency of administration and the dosage of said composition according the infant to whom it is administered.
  • the composition is administered daily from birth until the infant is at least one week old, more preferably at least two weeks old.
  • the composition is administered at least once a day to the infant for at least a period of one week, more preferably at least two weeks.
  • the inventors observed that the ENS of newborns was improved when lactic acid bacteria were administered. Therefore in one embodiment, a strain of these bacteria or the present composition comprising at least one strain of lactic acid bacteria is used for use in enhancing the maturation of the ENS in infants. Therefore in one embodiment, a strain of these bacteria or the present composition comprising at least one strain of lactic acid bacteria is for use in improving the maturation of the ENS in infants.
  • the strain of lactic acid bacteria or the composition comprising at least one strain of lactic acid bacterium is for use in infants in decreasing gastro-intestinal transit time, increasing gastro-intestinal motility, increasing gastro-intestinal muscle contractility, increasing gastro-intestinal peristalsis, preventing delayed gastric emptying, increasing coordinated contractions of the gastro-intestinal system, decreasing the time of meconium evacuation, decreasing the time at which gastro-intestinal motility starts after birth, permitting earlier enteral feeding (tolerance) after birth, and reducing parental feeding time after birth.
  • the strain of lactic acid bacteria or the composition comprising at least one strain of lactic acid bacterium is for use in infants in treating and/or preventing an enteric nervous system related disorder selected from the group consisting of ileus, gastroparesis, abdominal distention, laparoschisis, dysmotility syndrome, and intestinal obstruction.
  • the disorder ileus is a disruption of the normal propulsive gastrointestinal motor activity often due to non-mechanical causes and includes for example post operative ileus, paralytic ileus, physiological ileus, acute colonic pseudo-obstruction and meconium ileus.
  • Meconium ileus is a condition where the meconium, the first stool of an infant composed of materials ingested during the time the infant spends in the uterus becomes thickened and congested in the ileum. No meconium is passed, and abdominal distension and vomiting appear soon after birth. Normally meconium should be completely passed by the end of the first few days of postpartum life.
  • Meconium ileus in context of the present invention also relates to the meconium plug syndrome, a disorder of the colon characterized by delayed passage of meconium and intestinal dilatation in which a tenacious mass of mucus prevents the meconium from passing. Intestinal obstruction includes atresia and/or stenosis of small intestine.
  • the lactic acid bacteria strains selected from the group consisting of Bifidobacterium breve DN 156 032 (CNCM 1-4321), Bifidobacterium animalis ATCC SD5220, Bifidobacterium animalis CNCM 1-2494, Lactobacillus plantarum CNCM I- 4318 and Bifidobacterium breve CNCM 1-2219, more preferably Bifidobacterium animalis CNCM 1-2494 and Lactobacillus plantarum CNCM 1-4318, were shown to increase the production of vaso-intestinal peptide (VIP) levels produced by enteric nervous system cells in an in vitro model in coculture with a monolayer of enteral epithelial cells (data not shown).
  • VIP vaso-intestinal peptide
  • Increased VIP levels advantageously result in decreased intestinal barrier (IEB) permeability. This is especially advantageous for the use in new born infants, who have an immature intestinal barrier function, and more particularly for the use in preterm infants with an even more impaired IEB function, even further decreased by stress. Increased VIP levels also advantageously result in an improved function of the ENS.
  • IEB intestinal barrier
  • the invention relates to a composition comprising lactic acid bacteria, wherein the lactic acid bacteria are selected from the group consisting of Bifidobacterium breve DN 156 032 (CNCM 1-4321), Lactobacillus plantarum DN 121 0304 (CNCM 1-4318), Bifidobacterium animalis ATCC SD5220, Bifidobacterium animalis DN 173 010 (CNCM 1-2494), and Bifidobacterium breve DN 156 007 (CNCM I- 2219), for use in rectal administration in infants, wherein the infant is preferably selected from the group consisting of premature infants, infants with a very low birth weight and infants delivered via Caesarean section, more preferably premature infants.
  • the lactic acid bacteria are selected from the group consisting of Bifidobacterium breve DN 156 032 (CNCM 1-4321), Lactobacillus plantarum DN 121 0304 (CNCM 1-4318), Bif
  • Newborn rats received from day 7 to day 17 after birth an enema (20 ⁇ /g body weight) comprising Bifidobacterium animalis Bi07 (Danisco; ATCC SD5220) or Bifidobacterium animalis CNCM 1-2494.
  • the dose was 2.10 7 cfu/day, administered in a volume of 20 ⁇ /g body weight.
  • a positive and negative control a butyrate solution (2.5 mM) and PBS (IX) was used respectively, and given at 20 ⁇ /g body weight.
  • newborn rats were sacrificed. Immunofluorescence staining
  • the mesenteric plexus of the proximal colon tissue was immuno- stained for Hu (protein used to label specifically neuronal cells), ChAT, and nNOS (neuronal nitric oxide synthase), by anti-HuC/HuD, anti-ChAT and anti-nNOS antibodies.
  • Hu protein used to label specifically neuronal cells
  • ChAT ChAT
  • nNOS neuronitric oxide synthase
  • LMMP longitudinal muscle and myenteric plexus
  • Tissues were then incubated sequentially with the primary antibodies for 3h and the secondary antibodies for lh in the following order: goat anti-ChAT (1 :200; Millipore, USA) and anti-goat Cy3 (carboxymethylindocyanine) (1 :500; Jackson Immuno Research, USA); rabbit anti-nNOS (1 : 1000; Alexis, USA) and anti-rabbit Cy5 (7-amino-4- indodicarbocyanin) (1 :500; Jackson Immuno Research, USA) and mouse anti-HuC/HuD (1 :200; Invitrogen, USA) and anti-mouse FITC (Flurorescein isothiocyanate) (1 :500; Jackson Immuno Research, USA).
  • goat anti-ChAT (1 :200; Millipore, USA
  • anti-goat Cy3 carboxymethylindocyanine
  • rabbit anti-nNOS (1 : 1000; Alexis, USA
  • results are expressed as mean +/- standard error of the mean (s.e.m.). Statistical differences were determined by paired -test or one way or two ways analysis of variance (ANOVA), followed by post hoc test, as appropriate, p values of 0.05 or less were considered statistically significant.
  • the body weight was significantly increased at day 21 in rats having received the enema with Bifidobacteria, compared to rats having received the buffer. No such effect on growth was observed with butyrate enemas. See Table 1.
  • the number of neurons per ganglion as determined by Hu staining was increased in rats receiving the Bifidobacteria strains comprising enemas, in particular strain CNCM 1-2494, compared to the placebo, see Table 2.
  • the quality of the neurons was improved.
  • the percentage of ChAT neurons was increased in rats receiving the lactic acid bacteria enemas, compared to the placebo, most significantly in rats receiving CNCM 1-2494, and the percentage of nNOS per neuron was increased in rats receiving the lactic acid bacteria enemas, compared to the placebo, see Table 2. Butyrate showed another effect. It did not have a significant effect on the number of neurons per ganglion, but did also increase ChAT/Hu and nNOS/Hu.
  • CNCM 1-2494 on the maturation of ENS of the gut, in particular on
  • Pregnant Sprague-Dawley rats were at 13-14 days of gestation. After delivery, mothers and their pups were kept in the same conditions during the whole experiment. Newborn rats received from day 7 to day 17 after birth an enema (20 ⁇ /g body weight) comprising Bifidobacterium animalis Bi07 or Lactobacillus plantarum CNCM I- 4318. Two daily doses were tested, being 10 5 and 10 7 cfu/day. As a negative control a PBS (IX) solution was used and given at 20 ⁇ /g body weight. At day 21, rats were sacrificed and the colon was dissected, proximal and distal colon samples were stored for analysis. Proximal colon refers to the ascending and transverse colon while distal colon refers to the descending colon.
  • IX PBS
  • the mesenteric plexus of the proximal and distal colon tissue was immuno- stained for VIP, according to the method as described in Example 1 , using anti-VIP antibodies.
  • Results are shown in Tables 3 and 4.
  • the VIP level is expressed in ng/ml ⁇ g total proteins.
  • Standard deviation (SD) is also indicated.
  • Enemas comprising lactic acid bacteria enhanced the VIP level in the proximal and distal colon. This effect was the highest with strain CNCM 1-4318.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à l'utilisation de bactéries d'acide lactique, destinées à être utilisées dans la maturation du système nerveux entérique chez les nouveau-nés.
PCT/IB2011/052336 2010-05-28 2011-05-27 Bactéries d'acide lactique destinées à la maturation du système nerveux entérique chez les nouveau-nés Ceased WO2011148352A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2010/001542 WO2011148221A1 (fr) 2010-05-28 2010-05-28 Bactérie lactique pour la maturation du système nerveux entérique chez les nourrissons
IBPCT/IB2010/001542 2010-05-28

Publications (1)

Publication Number Publication Date
WO2011148352A1 true WO2011148352A1 (fr) 2011-12-01

Family

ID=43334520

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2010/001542 Ceased WO2011148221A1 (fr) 2010-05-28 2010-05-28 Bactérie lactique pour la maturation du système nerveux entérique chez les nourrissons
PCT/IB2011/052336 Ceased WO2011148352A1 (fr) 2010-05-28 2011-05-27 Bactéries d'acide lactique destinées à la maturation du système nerveux entérique chez les nouveau-nés

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001542 Ceased WO2011148221A1 (fr) 2010-05-28 2010-05-28 Bactérie lactique pour la maturation du système nerveux entérique chez les nourrissons

Country Status (1)

Country Link
WO (2) WO2011148221A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2734049T3 (en) 2011-06-20 2018-07-30 Heinz Co Brands H J Llc PROBIOTIC COMPOSITIONS AND PROCEDURES
US9980991B2 (en) 2013-05-10 2018-05-29 H.J. Heinz Company Brands Llc Probiotics and methods of use
CN109957530B (zh) * 2019-03-19 2021-12-07 江西仁仁健康产业有限公司 一种植物乳杆菌及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001785A1 (fr) 1999-07-06 2001-01-11 Compagnie Gervais Danone Procede de preparation d'un produit lacte immunostimulant et ses applications
EP1161152A1 (fr) 1999-03-12 2001-12-12 Societe Des Produits Nestle S.A. Composition nutritionnelle destinee a une maturation gastro-intestinale specifique chez des mammiferes prematures
WO2002002800A1 (fr) 2000-07-04 2002-01-10 Compagnie Gervais Danone Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales
WO2004112509A2 (fr) 2003-06-23 2004-12-29 Nestec S.A. Formule nutritionnelle pour fonction de barriere intestinale optimale
WO2007140622A1 (fr) * 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques dérivées de produits laitiers et leurs utilisations
WO2009151329A1 (fr) * 2008-06-13 2009-12-17 N.V. Nutricia Composition nutritionnelle permettant la prévention d’infections
WO2010002241A1 (fr) * 2008-06-30 2010-01-07 N.V. Nutricia Composition nutritive pour bébés nés par césarienne

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161152A1 (fr) 1999-03-12 2001-12-12 Societe Des Produits Nestle S.A. Composition nutritionnelle destinee a une maturation gastro-intestinale specifique chez des mammiferes prematures
WO2001001785A1 (fr) 1999-07-06 2001-01-11 Compagnie Gervais Danone Procede de preparation d'un produit lacte immunostimulant et ses applications
WO2002002800A1 (fr) 2000-07-04 2002-01-10 Compagnie Gervais Danone Microorganismes ayant une action modulatrice de la glycosylation de surface des cellules intestinales
WO2004112509A2 (fr) 2003-06-23 2004-12-29 Nestec S.A. Formule nutritionnelle pour fonction de barriere intestinale optimale
WO2007140622A1 (fr) * 2006-06-09 2007-12-13 Nutravital Inc. Compositions probiotiques dérivées de produits laitiers et leurs utilisations
WO2009151329A1 (fr) * 2008-06-13 2009-12-17 N.V. Nutricia Composition nutritionnelle permettant la prévention d’infections
WO2010002241A1 (fr) * 2008-06-30 2010-01-07 N.V. Nutricia Composition nutritive pour bébés nés par césarienne

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Bergey's manual of systematic Bacteriology", vol. 2, 1986, WILLIAMS & WILKINS, pages: 635
INDRIO ET AL., J PEDIATR, vol. 152, 2008, pages 801 - 806
INDRIO F ET AL: "The Effects of Probiotics on Feeding Tolerance, Bowel Habits, and Gastrointestinal Motility in Preterm Newborns", JOURNAL OF PEDIATRICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, vol. 152, no. 6, 1 June 2008 (2008-06-01), pages 801 - 806, XP022663571, ISSN: 0022-3476, [retrieved on 20071226], DOI: DOI:10.1016/J.JPEDS.2007.11.005 *
SAMBROOK J., FRITSCH, E.F., MANIATIS, T.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR (N.Y.) LABORATORY PRESS
SAMBROOK, J., FRITSCH, E.F., MANIATIS, T.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR (N.Y.) LABORATORY PRESS
SCARDOVI V.: "Genus Bifidobacterium", GENUS BIFIDOBACTERIUM, pages 1418,1434
TABBERS MERIT M ET AL: "Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571).", BMC PEDIATRICS 2009 LNKD- PUBMED:19296845, vol. 9, 2009, pages 22, XP021049132, ISSN: 1471-2431 *

Also Published As

Publication number Publication date
WO2011148221A1 (fr) 2011-12-01

Similar Documents

Publication Publication Date Title
RU2762984C2 (ru) Способ стимуляции кишечной флоры
RU2456008C2 (ru) Синбиотик для улучшения кишечной микробиоты
EP2285387B1 (fr) Composition nutritionnelle permettant la prévention d infections
ES2647922T3 (es) Agente anti-obesidad, alimento o bebida anti-obesidad, agente que mejora la tolerancia a la glucosa, y alimento o bebida para mejorar la tolerancia a la glucosa
JP6197045B2 (ja) ビフィドバクテリウム・アニマリスｓｓｐ．アニマリスの株
CN109105879A (zh) 含有不可消化寡糖的发酵婴儿配方物
CN105722409A (zh) 用于预防或治疗婴儿和幼儿的坏死性小肠结肠炎的组合物
CN109069555B (zh) 面向新生儿的用于改善脑功能的组合物
CN117377397A (zh) 合生素组合物
CN105848499A (zh) 含有不可消化寡糖的发酵配方物
RU2724536C2 (ru) Ферментированная молочная смесь с неперевариваемыми олигосахаридами
CN108697141A (zh) 含有不可消化寡糖和非复制型产乳酸细菌的营养配方物
WO2011148352A1 (fr) Bactéries d'acide lactique destinées à la maturation du système nerveux entérique chez les nouveau-nés
CN109688839A (zh) 发酵的婴儿配方物
US20160206658A1 (en) Nutrition for prevention of infections
Hoppe et al. Commercially available human probiotic microorganisms
WO2020229689A1 (fr) Préparation pour nourrissons fermentée pour améliorer le développement intestinal
Beccati Investigations of prebiotics and of inter-and intra-molecular glycan-protein interactions
Kumar et al. Probiotics: biotechnology in prolongation of life
NZ719161B2 (en) Fermented formula with non digestible oligosaccharides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745576

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11745576

Country of ref document: EP

Kind code of ref document: A1